The subject of this book is applied Bayesian methods for chemistry, manufacturing, and control (CMC) studies in the biopharmaceutical industry. The book has multiple authors from industry and academia, each contributing a case study (chapter). The collection of case studies covers a broad array of CMC topics, including stability analysis, analytical method development, specification setting, process development and optimization, process control, experimental design, dissolution testing, and comparability studies. The analysis of each case study includes a presentation of code and reproducible output. This book is written with an academic level aimed at practicing nonclinical biostatisticians, most of whom have graduate degrees in statistics. • First book of its kind focusing strictly on CMC Bayesian case studies • Case studies with code and output • Representation from several companies across the industry as well as academia • Authors are leading and well-known Bayesian statisticians in the CMC field • Accompanying website with code for reproducibility • Reflective of real-life industry applications/problems

Drug development is a strictly regulated area. As such, marketing approval of a new drug depends heavily, if not exclusively, on evidence generated from clinical trials. Drug development has seen tremendous innovation in science and technology that has revolutionized the treatment of some diseases. And yet, the statistical design and practical conduct of the clinical trials used to test new therapeutics for safety and efficacy have changed very little over the decades. Our approach to clinical trials is steeped in convention and tradition. The large, fixed, randomized controlled trial methods that have been the gold standard are well understood and expected by many trial stakeholders. However, this approach is not well suited to all aspects of modern drug development and the current competitive landscape. We now see new therapies that target a small fraction of the patient population, rare diseases with high unmet medical needs, and pediatric populations that must wait for years for new drug approvals from the time that therapies are approved in adults. Large randomized clinical trials are at best inefficient and at worst completely infeasible in many modern clinical settings. Advances in technology and data infrastructure call for innovations in clinical trial design. Despite advances in statistical methods, the availability of information, and computing power, the actual experience with innovative design in clinical trials across industry and academia is limited. This book will be an important showcase of the potential for these innovative designs in modern drug development and will be an important resource to guide those who wish to undertake them for themselves. This book is ideal for professionals in the pharmaceutical industry and regulatory agencies, but it will also be useful to academic researchers, faculty members, and graduate students in statistics, biostatistics, public health, and epidemiology due to its focus on innovation. Key Features: Is written by pharmaceutical industry experts, academic researchers, and regulatory reviewers; this is the first book providing a comprehensive set of case studies related to statistical methodology, implementation, regulatory considerations, and communication of complex innovative trial design Has a broad appeal to a multitude of readers across academia, industry, and regulatory agencies Each contribution is a practical case study that can speak to the benefits of an innovative approach but also balance that with the real-life challenges encountered A complete understanding of what is actually being done in modern clinical trials will broaden the reader’s capabilities and provide examples to first mimic and then customize and expand upon when exploring these ideas on their own

Bayesian Precision Medicine presents modern Bayesian statistical models and methods for identifying treatments tailored to individual patients using their prognostic variables and predictive biomarkers. The process of evaluating and comparing treatments is explained and illustrated by practical examples, followed by a discussion of causal analysis and its relationship to statistical inference. A wide array of modern Bayesian clinical trial designs are presented, including applications to many oncology trials. The later chapters describe Bayesian nonparametric regression analyses of datasets arising from multistage chemotherapy for acute leukemia, allogeneic stem cell transplantation, and targeted agents for treating advanced breast cancer. Features: Describes the connection between causal analysis and statistical inference Reviews modern personalized Bayesian clinical trial designs for dose-finding, treatment screening, basket trials, enrichment, incorporating historical data, and confirmatory treatment comparison, illustrated by real-world applications Presents adaptive methods for clustering similar patient subgroups to improve efficiency Describes Bayesian nonparametric regression analyses of real-world datasets from oncology Provides pointers to software for implementation Bayesian Precision Medicine is primarily aimed at biostatisticians and medical researchers who desire to apply modern Bayesian methods to their own clinical trials and data analyses. It also might be used to teach a special topics course on precision medicine using a Bayesian approach to postgraduate biostatistics students. The main goal of the book is to show how Bayesian thinking can provide a practical scientific basis for tailoring treatments to individual patients.

Many conventional survival analysis methods, such as the Kaplan-Meier method for survival function estimation and the partial likelihood method for Cox model regression coefficients estimation, were developed under the assumption that survival times are subject to right censoring only. However, in practice, survival time observations may include interval-censored data, especially when the exact time of the event of interest cannot be observed. When interval-censored observations are present in a survival dataset, one generally needs to consider likelihood-based methods for inference. If the survival model under consideration is fully parametric, then likelihood-based methods impose neither theoretical nor computational challenges. However, if the model is semi-parametric, there will be difficulties in both theoretical and computational aspects. Likelihood Methods in Survival Analysis: With R Examples explores these challenges and provides practical solutions. It not only covers conventional Cox models where survival times are subject to interval censoring, but also extends to more complicated models, such as stratified Cox models, extended Cox models where time-varying covariates are present, mixture cure Cox models, and Cox models with dependent right censoring. The book also discusses non-Cox models, particularly the additive hazards model and parametric log-linear models for bivariate survival times where there is dependence among competing outcomes. Features Provides a broad and accessible overview of likelihood methods in survival analysis Covers a wide range of data types and models, from the semi-parametric Cox model with interval censoring through to parametric survival models for competing risks Includes many examples using real data to illustrate the methods Includes integrated R code for implementation of the methods Supplemented by a GitHub repository with datasets and R code The book will make an ideal reference for researchers and graduate students of biostatistics, statistics, and data science, whose interest in survival analysis extend beyond applications. It offers useful and solid training to those who wish to enhance their knowledge in the methodology and computational aspects of biostatistics.

Disease screening and disease surveillance (DSDS) constitute two critical areas in public health, each presenting distinctive challenges primarily due to their sequential decision-making nature and complex data structures. Statistical Methods for Dynamic Disease Screening and Spatio-Temporal Disease Surveillance explores numerous recent analytic methodologies that enhance traditional techniques. The author, a prominent researcher specializing in innovative sequential decision-making techniques, demonstrates how these novel methods effectively address the challenges of DSDS. After a concise introduction that lays the groundwork for comprehending the challenges inherent in DSDS, the book delves into fundamental statistical concepts and methods relevant to DSDS. This includes exploration of statistical process control (SPC) charts specifically crafted for sequential decision-making purposes. The subsequent chapters systematically outline recent advancements in dynamic screening system (DySS) methods, fine-tuned for effective disease screening. Additionally, the text covers both traditional and contemporary analytic methods for disease surveillance. It further introduces two recently developed R packages designed for implementing DySS methods and spatio-temporal disease surveillance techniques pioneered by the author's research team. Features • Presents Recent Analytic Methods for DSDS: The book introduces analytic methods for DSDS based on SPC charts. These methods effectively utilize all historical data, accommodating the complex data structure inherent in sequential decision-making processes. • Introduces Recent R Packages: Two recent R packages, DySS and SpTe2M, are introduced. The book not only presents these packages but also demonstrates key DSDS methods using them. • Examines Recent Research Results: The text delves into the latest research findings across various domains, including dynamic disease screening, nonparametric spatio-temporal data modeling and monitoring, and spatio-temporal disease surveillance. • Accessible Description of Methods: Major methods are described in a manner accessible to individuals without advanced knowledge in mathematics and statistics. The goal is to facilitate a clear understanding of ideas and easy implementation. • Real-Data Examples: To aid comprehension, the book provides several real-data examples illustrating key concepts and methods. • Hands-on Exercises: Each chapter includes exercises to encourage hands-on practice, allowing readers to engage directly with the presented methods.

• Presents an overview of methods and applications of health disparity estimation • First book to synthesize research in this field in a unified statistical framework • Covers classical approaches, and builds to more modern computational techniques • Includes many worked examples and case studies using real data • Discusses available software for estimation

Specification of Drug Substances and Drug Products is a fully comprehensive reference on Specification Setting for Pharmaceuticals. There have been several recent developments in the ICH Guidelines, which were not captured in previous editions, notably the new guideline on Development of Analytical Procedure and the revisions to the validation guidelines, and the specification guidelines. This edition contains chapters discussing the unique requirements for the universal critical quality attributes, as well as the specific tests required to characterize and control different types of products, ranging in complexity from small molecules in immediate release oral dosage forms to complex products such as drug-antibody conjugates and mRNA-based products. This substantially expanded revision of the 2nd edition will serve as practical comprehensive reference for scientists, managers, educators, and consultants involved in the development and regulation of pharmaceutical products - Presents critical assessment, potential impact, and application of the recent revisions to ICH guidelines on method validation (Q2) (as well as the latest guideline on Analytical Method Development (Q14), and the special regional requirements in non-ICH regions. - Addresses comprehensive treatment of the development and validation of analytical methodologies used in the analysis, control, and specification of a variety of different types of dosage forms, ranging from traditional oral solid dosage forms to proteins, nRNA-based drugs, vaccines, and gene therapy. This book will also address drug–device combination products such as digital drug delivery systems, transdermal systems, and inhalation products. - Presents detailed treatment of latest statistical approaches, including new approaches to the treatment of validation data method, specification setting, and shelf-life prediction (based on stability data).

This book begins with an introduction of pragmatic cluster randomized trials (PCTs) and reviews various pragmatic issues that need to be addressed by statisticians at the design stage. It discusses the advantages and disadvantages of each type of PCT, and provides sample size formulas, sensitivity analyses, and examples for sample size calculation. The generalized estimating equation (GEE) method will be employed to derive sample size formulas for various types of outcomes from the exponential family, including continuous, binary, and count variables. Experimental designs that have been frequently employed in PCTs will be discussed, including cluster randomized designs, matched-pair cluster randomized design, stratified cluster randomized design, stepped-wedge cluster randomized design, longitudinal cluster randomized design, and crossover cluster randomized design. It demonstrates that the GEE approach is flexible to accommodate pragmatic issues such as hierarchical correlation structures, different missing data patterns, randomly varying cluster sizes, etc. It has been reported that the GEE approach leads to under-estimated variance with limited numbers of clusters. The remedy for this limitation is investigated for the design of PCTs. This book can assist practitioners in the design of PCTs by providing a description of the advantages and disadvantages of various PCTs and sample size formulas that address various pragmatic issues, facilitating the proper implementation of PCTs to improve health care. It can also serve as a textbook for biostatistics students at the graduate level to enhance their knowledge or skill in clinical trial design. Key Features: Discuss the advantages and disadvantages of each type of PCTs, and provide sample size formulas, sensitivity analyses, and examples. Address an unmet need for guidance books on sample size calculations for PCTs; A wide variety of experimental designs adopted by PCTs are covered; The sample size solutions can be readily implemented due to the accommodation of common pragmatic issues encountered in real-world practice; Useful to both academic and industrial biostatisticians involved in clinical trial design; Can be used as a textbook for graduate students majoring in statistics and biostatistics.

This book covers classic epidemiological designs that use a reference/control group, including case-control, case-cohort, nested case-control and variations of these designs, such as stratified and two-stage designs. It presents a unified view of these sampling designs as representations of an underlying cohort or target population of interest. This enables various extended designs to be introduced and analysed with a similar approach: extreme sampling on the outcome (extreme case-control design) or on the exposure (exposure-enriched, exposure-density, countermatched), designs that re-use prior controls and augmentation sampling designs. Further extensions exploit aggregate data for efficient cluster sampling, accommodate time-varying exposures and combine matched and unmatched controls. Self-controlled designs, including case-crossover, self-controlled case series and exposure-crossover, are also presented. The test-negative design for vaccine studies and the use of negative controls for bias assessment are introduced and discussed. This book is intended for graduate students in biostatistics, epidemiology and related disciplines, or for health researchers and data analysts interested in extending their knowledge of study design and data analysis skills. This book Bridges the gap between epidemiology and the more mathematically oriented biostatistics books. Assembles the wealth of epidemiological knowledge about observational study designs that is scattered over several decades of scientific publications. Illustrates the performance of methods in real research applications. Provides guidelines for implementation in standard software packages (Stata, R). Includes numerous exercises, covering simple mathematical proofs, consideration of proposed or published designs, and practical data analysis.

Cell and gene therapies have become the third major drug modality in pharmaceutical medicine of the 21st century after low molecular weight and antibody drugs. The gene therapy (GTx) field is rapidly advancing, and yet there are still fundamental scientific questions that remain to be answered. Development of GTx products poses unique challenges and opportunities for drug developers. However, there is lack of a systematic exposition of the GTx product development and the pivotal role of the biostatistician in this process. Development of Gene Therapies: Strategic, Scientific, and Regulatory, and Access Considerations attempts to summarize the current state-of-the-art strategic, scientific, statistical, and regulatory aspects of GTx development. Intended to provide an exposition to the GTx new product development through peer-reviewed papers written by subject matter experts in this emerging field, this book will be useful for researchers in gene therapy drug development, biostatisticians, regulators, patient advocates, graduate students, and the finance and business development community . Key Features: A collection of papers covering a wide spectrum of topics in gene therapies (GTx), written by leading subject matter experts An exposition of the core principles of GTx product development, emerging business models, industry standards, best practices, and regulatory pathways An exposition of statistical and innovative modeling tools for design and analysis of clinical trials of GTx Insights into commercial models, access hurdles, and health economics of gene therapies Case studies of successful GTx approvals from core team members that developed the first two FDA-approved AAV gene therapies: Luxturna and Zolgensma A discussion of potential benefits and hurdles to be overcome for GTx in coming years from a multi-stakeholder perspective